CAMBRIDGE, Mass., Aug. 25, 2022 -- Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced...
Repurposing a cholesterol drug candidate for cholestatic liver disease
News | 06. 19. 2013
Lumena Pharmaceuticals
June 19, 2013
Lumena Pharmaceuticals Inc. is converting a compound previously tested as a cholesterol-lowering agent into an experimental treatment for cholestatic liver diseases. The molecule inhibits a so-called transporter that normally helps the body recycle bile acid.
